View More Recent Stories

Nov 6, 2024 07:12AM Rhythm Pharmaceuticals (RYTM) PT Raised to $64 at Needham
Nov 6, 2024 05:28AM Rhythm Pharmaceuticals (RYTM) PT Raised to $59 at Goldman Sachs
Nov 5, 2024 04:13PM Rhythm Pharmaceuticals (RYTM) Tops Q3 EPS by 7c
Oct 25, 2024 08:04AM H.C. Wainwright Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
Oct 7, 2024 06:34AM H.C. Wainwright Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
Sep 17, 2024 01:55AM JMP Securities Starts Rhythm Pharmaceuticals (RYTM) at Market Outperform
Aug 26, 2024 08:02AM Rhythm Pharmaceuticals (RYTM) Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE in Patients as Young as 2 years old
Aug 7, 2024 07:03AM Rhythm Pharmaceuticals (RYTM) PT Lowered to $77 at Canaccord Genuity
Jul 31, 2024 09:11AM Rhythm Pharmaceuticals (RYTM) Announces European Commission Expands IMCIVREE Marketing Authorization to include Children as Young as 2 Years Old
Jul 25, 2024 07:39AM Rhythm Pharmaceuticals (RYTM) PT Raised to $55 at Needham
Jul 8, 2024 08:00AM Rhythm Pharmaceuticals (RYTM) Appoint Alastair Garfield as Chief Scientific Officer
Jun 28, 2024 08:01AM Rhythm Pharmaceuticals (RYTM) Receives Positive CHMP Opinion for IMCIVREE
Apr 5, 2024 01:00PM M&A watch: 3 biotech companies that are most likely to be acquired - Needham
View More Recent Stories